This page shows the latest Hodgkin's lymphoma news and features for those working in and with pharma, biotech and healthcare.
Roche's fixed-duration bispecific antibody Columvi (glofitamab) has been granted conditional marketing authorisation by the European Commission (EC) to treat adults with an aggressive form of lymphoma. ... Each year in Europe, an estimated 36, 000 people
Globally around 160, 000 people are diagnosed with non-Hodgkin's lymphoma each year. ... Around 160, 000 people worldwide are estimated to be diagnosed each year with DLBCL – the most common form of non-Hodgkin's lymphoma.
The candidates have shown the potential to treat forms of non-Hodgkin’s lymphoma. ... The investigational CAR-Ts have shown promising early-stage results in patients with relapsed/refractory non-Hodgkin’s lymphoma (NHL), the companies said, with the
Hodgkin lymphoma (cHL), in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide (AVE-PC). ... The study enrolled 587 patients aged from two to 21 years across 151 institutions who had previously untreated Hodgkin
BeiGene’s Brukinsa (zanubrutinib) has been approved by the European Commission (EC) for the treatment of adult patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL) who have received at ... BTK inhibitor for marginal zone lymphoma in
of investigational epcoritamab in adult patients with relapsed, progressive or refractory CD20+ mature B-cell non-Hodgkin's lymphoma (NHL), including DLBCL. ... large B-cell lymphoma and diffuse large B-cell lymphoma who have limited treatment options.
More from news
Approximately 22 fully matching, plus 157 partially matching documents found.
One of the best known pharma leaders in China, Dr Wu’s most recent achievement was to build Pfizer into one of the top multinational firms in China. ... CDA). The company is filing first for patients with relapsed/refractory classical Hodgkin’s
Zykadia is approved in the US for patients with anaplastic lymphoma kinase (ALK) and metastatic NSCLC but not approved elsewhere; INC 280 and EFG 816 are in phase 1 development; the ... Hodgkin's lymphoma.
The company has also out-licensed a non-small cell lung cancer treatment (Tarceva) and non-Hodgkin's lymphoma treatment (bendamustine) to its strategic partners, with several prospective new oncology medications ... So that's where we need the diversity,
The significance of this lays in the evolving nature of Takeda's portfolio. ... Even closer to market is Takeda's monoclonal antibody treatment for Hodgkin's Lymphoma, Adcetris (brentuximab vedotin), which was recommended for European approval in July
More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.
Previously worked in oncology for Allos, Cephalon and AstraZeneca. Immunogen has appointed Dr Charles Morris as the company's chief development officer. ... cancers that over-express folate receptor 1, and IMGN529 - in phase I testing for the treatment
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Naming diseases after people, places and animals has been common practice throughout the world for centuries, from the more current examples of Swine flu and Lyme disease to 19th century ... s Lymphoma and Parkinsons.
Therapy Watch CML is part of a wider oncology portfolio which already covers Chronic Lymphocytic Leukaemia (CLL), Non-Hodgkin's Lymphoma (NHL), Melanoma, Non-Small Cell Lung Cancer (NSCLC), Prostate Cancer
Therapy Watch SCCHN is part of a wider portfolio which covers Chronic Lymphocytic Leukaemia (CLL), Non-Hodgkin's Lymphoma (NHL), Melanoma, Non-Small Cell Lung Cancer (NSCLC), Prostate Cancer (PCa), Renal
Pixuvri: Polycomparator segmentation by the G-BA removes statistical power. Cell Therapeutics gained European approval for Pixuvri (pixantrone) in non-Hodgkin’s B-cell lymphoma, on the basis of a trial ... against ‘treatment of physician’s
More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.
No results were found
JPA Health is an award-winning public relations, marketing and advocacy firm known for sharing our clients’ commitment to making people...